Cerevel Therapeutics Inc... (CERE)
NASDAQ: CERE
· Real-Time Price · USD
44.96
0.33 (0.74%)
At close: Jul 31, 2024, 10:00 PM
Cerevel Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 8.25M | 8.25M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 5.85M | 5.63M | 5.42M | 5.24M | 5.11M | 4.9M | 5.25M | 4.96M | 4.34M | 3.29M | 1.64M | 664K | 63K |
Gross Profit | 2.4M | 2.62M | -5.42M | -5.24M | -5.11M | -4.9M | -5.25M | -4.96M | -4.34M | -3.29M | -1.64M | -664K | -63K |
Operating Income | -490.37M | -447.26M | -414.95M | -398.71M | -394.87M | -367.85M | -325.09M | -284.55M | -242.06M | -220.1M | -197.5M | -177.34M | -161.99M |
Interest Income | 49.24M | 41.23M | 32.1M | 26.2M | 17.05M | 10.9M | 5.07M | 1.09M | 437K | 157K | 52K | 40K | 35K |
Pretax Income | -459.91M | -432.34M | -392.51M | -396.21M | -387.26M | -351.35M | -317.76M | -279.88M | -242.65M | -225.33M | -199.46M | -176.44M | -149.94M |
Net Income | -460.47M | -432.84M | -392.99M | -401.44M | -392.38M | -352.15M | -318.39M | -275.64M | -238.41M | -225.33M | -199.46M | -176.44M | -149.91M |
Selling & General & Admin | 125.98M | 111.12M | 96.12M | 93.75M | 91.45M | 87.59M | 78.3M | 68.99M | 61.74M | 58.24M | 53.35M | 49.32M | 49.08M |
Research & Development | 362.88M | 334.64M | 318.83M | 304.96M | 303.42M | 280.26M | 246.79M | 215.56M | 180.32M | 161.85M | 144.15M | 128.02M | 112.91M |
Other Expenses | -2.86M | -13.03M | -4.38M | -12.19M | -2.41M | 8.68M | 5.35M | -2.22M | -4.97M | -5.39M | -10.71M | -3.16M | -425K |
Operating Expenses | 488.87M | 445.76M | 414.95M | 398.71M | 394.87M | 367.85M | 325.09M | 284.55M | 242.06M | 220.1M | 197.5M | 177.34M | 161.99M |
Interest Expense | 10.58M | 14.37M | 17.68M | 16.32M | 13.68M | 7.53M | 1.7M | 427K | 437K | 157K | 52K | 40K | 35K |
Selling & Marketing Expenses | -1.5M | -1.5M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 490.37M | 447.26M | 414.95M | 398.71M | 394.87M | 367.85M | 325.09M | 284.55M | 242.06M | 220.1M | 197.5M | 177.34M | 161.99M |
Income Tax Expense | 556K | 503K | 475K | 5.22M | 5.13M | 805K | 764K | -4.12M | -4.14M | 81K | -41K | -33K | -39K |
Shares Outstanding (Basic) | 181.61M | 174.6M | 157.5M | 157.05M | 156.65M | 156.37M | 152.3M | 148.3M | 147.98M | 147.3M | 144.02M | 127.48M | 127.23M |
Shares Outstanding (Diluted) | 181.61M | 174.6M | 157.5M | 157.05M | 156.65M | 156.37M | 152.3M | 148.3M | 147.98M | 147.3M | 144.02M | 127.48M | 127.23M |
EPS (Basic) | -2.73 | -2.67 | -2.5 | -2.58 | -2.56 | -2.32 | -2.13 | -1.87 | -1.68 | -1.65 | -1.55 | -1.43 | -1.22 |
EPS (Diluted) | -2.73 | -2.67 | -2.5 | -2.58 | -2.56 | -2.32 | -2.13 | -1.87 | -1.68 | -1.65 | -1.55 | -1.43 | -1.22 |
EBITDA | -466.75M | -423.87M | -379.16M | -382.08M | -377.75M | -350.64M | -320.69M | -280.15M | -239.56M | -219.01M | -191.94M | -171.73M | -156.18M |
EBIT | -461.13M | -417.97M | -374.84M | -379.9M | -376.12M | -346.35M | -318.59M | -281.99M | -242.21M | -225.18M | -193.92M | -170.92M | -150.35M |
Depreciation & Amortization | 5.85M | 5.63M | 5.42M | 5.24M | 5.11M | 4.9M | 5.25M | 4.96M | 4.34M | 3.29M | 1.71M | 776K | 365K |